<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974428</url>
  </required_header>
  <id_info>
    <org_study_id>A077-ATR08H</org_study_id>
    <nct_id>NCT00974428</nct_id>
  </id_info>
  <brief_title>Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis</brief_title>
  <official_title>A 6 Week, Double Blind, Placebo-controlled, Multi-center Pilot Study Evaluating the Efficacy of Wobenzym(R)N at Reducing Pain Severity as Measured by the WOMAC Pain Score in Subjects With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Innovations</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Innovations</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the most effective dose of Wobenzym® N versus&#xD;
      placebo at reducing pain severity as measured by the WOMAC pain score in subjects with&#xD;
      symptomatic knee osteoarthritis (OA) at 6 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is the most common disease of the joints. The main symptom of OA is pain&#xD;
      and later followed by stiffness and decreased function of the joints. It is estimated to&#xD;
      affect more than 100 million people worldwide, substantially decreasing their quality of&#xD;
      their life. Treatment that can relieve the disease symptoms and more particularly the pain&#xD;
      level can greatly improve the quality of life and function of patients suffering from OA of&#xD;
      weight-bearing joints such as the knee. Wobenzym® N is a fixed compound made of plant and&#xD;
      animal enzyme products with the non-enzymatic component rutin recommended for the treatment&#xD;
      of musculoskeletal disorders. The Wobenzym® N formulation contains, per tablet: pancreatin&#xD;
      100 mg, trypsin 24 mg and chymotrypsin 1 mg (from pancreas); bromelain 45 mg; papain 60 mg;&#xD;
      and rutin 50 mg.&#xD;
&#xD;
      Over 50 clinical studies have been conducted using similar oral proteolytic enzyme&#xD;
      preparations-- Wobenzym® and Phlogenzym®-- with consistently positive findings related to&#xD;
      rheumatoid arthritis, sprains and strains, reduction of C-reactive protein, sports injuries&#xD;
      and joint and muscular pain, as well as OA of the knee. Several comparative studies conducted&#xD;
      with Phlogenzym®, an oral enzyme-rutin combination containing bromelain 90 mg, trypsin 48 mg&#xD;
      and rutin 100 mg, have proved the product to be effective and safe in the treatment of OA as&#xD;
      compared to NSAIDs. [For review, see Leipner, et al. Biodrugs 2001;15(12):779-89.]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the most effective dose of Wobenzym® N on the reduction of pain severity, measured by the WOMAC Osteoarthritis Index.</measure>
    <time_frame>Baseline (day 0), Week 3 (day 21) and Week 6 (day 42)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Global assessment</measure>
    <time_frame>Week 3 (day 21) and Week 6 (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of pain (VAS)</measure>
    <time_frame>Baseline (day 0), Week 3 (day 21) and Week 6 (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory profile (serum biomarkers) in serum samples</measure>
    <time_frame>Screening visit (-30 days prior day 0) and Week 6 (day 42)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Wobenzym® N and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wobenzym® N</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wobenzym® N 4 tablets three times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 4 tablets three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wobenzym® N</intervention_name>
    <description>4 tablets TID, 6 weeks</description>
    <arm_group_label>Wobenzym® N</arm_group_label>
    <arm_group_label>Wobenzym® N and placebo</arm_group_label>
    <other_name>None known.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablets TID</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Wobenzym® N and placebo</arm_group_label>
    <other_name>None known.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory outpatients of either sex, between 45 and 80 years of age, inclusively,&#xD;
             with primary OA of the knee meeting the classification criteria set by the American&#xD;
             College of Rheumatology (ACR; Appendix C.1), and who are not expected to require&#xD;
             surgical treatment for at least three (3) months after inclusion (Visit 1).&#xD;
&#xD;
          -  Women of childbearing potential must agree to use an adequate contraception&#xD;
             (abstinence; device mechanical barrier contraception; male partner sterilized)&#xD;
             beginning at least seven days prior to treatment (oral birth control pill should begin&#xD;
             at least 4 weeks prior to treatment) and continuing at least 14 days after Visit 4 or&#xD;
             the discontinuation visit. A serum or urine pregnancy test will be performed at Visit&#xD;
             1.&#xD;
&#xD;
          -  Functional Capacity Classification (Appendix C.2) of I-III at Visit 1.&#xD;
&#xD;
          -  Except for OA, the subject is judged to be in otherwise general good health based on&#xD;
             medical history, physical examination, and routine laboratory tests (Appendix B).&#xD;
&#xD;
          -  Subjects with a WOMAC pain subscale index of at least 40 mm and less than or equal to&#xD;
             90 mm (VAS) at the Baseline Visit after a 24-hour washout of any analgesics and a&#xD;
             minimum of 7 days washout of any NSAIDs (Appendix C.3 &amp; 4).&#xD;
&#xD;
          -  Subjects with OA of the contra-lateral knee will be included provided contra-lateral&#xD;
             knee OA pain intensity is inferior to the index knee.&#xD;
&#xD;
          -  Able to understand and complete study questionnaires including questions requiring a&#xD;
             visual analog scale (VAS) response (Appendix C.4).&#xD;
&#xD;
          -  Willing to participate in this study for approximately ten weeks.&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
          -  Subject agreed to follow the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to the use of Wobenzym® N (including allergy).&#xD;
&#xD;
          -  Concurrent medical/arthritic disease that could confound or interfere with the&#xD;
             monitoring of efficacy including, but no limited to: Inflammatory arthritis (e.g.,&#xD;
             rheumatoid arthritis), systemic lupus, spondyloarthropathy, psoriatic arthropathy,&#xD;
             Reiter's syndrome, ankylosing spondylitis, arthritis associated with inflammatory&#xD;
             bowel disease, polymyalgia rheumatica and gout or pseudogout of the index knee,&#xD;
             Paget's disease affecting the study joint, a history of septic arthritis or&#xD;
             intra-articular fracture of the study joint, osteochondritis, dessicans or&#xD;
             osteonecrosis of the study joint, Wilson's disease, haemochromatosis, ochronosis,&#xD;
             chondrocalcinosis or primary osteochondromatosis.&#xD;
&#xD;
          -  Significant injury of the study joint within three months of the Baseline visit as per&#xD;
             investigator judgment.&#xD;
&#xD;
          -  Subjects with Class IV functional capacity using the ACR criteria.&#xD;
&#xD;
          -  Subjects who had meniscal surgery on the study knee.&#xD;
&#xD;
          -  Subjects who have undergone total joint replacement of the contra-lateral knee within&#xD;
             six months prior to the Screening Visit (Visit 1).&#xD;
&#xD;
          -  Any clinical signs or laboratory evidence for severe renal/liver/pulmonary,&#xD;
             neurological, cardiovascular, metabolic, haematological, or psychiatric condition&#xD;
             which in the Investigator's opinion contraindicates a 6 week course of therapy with&#xD;
             Wobenzym® N.&#xD;
&#xD;
          -  Subject is, in the opinion of the investigator, mentally or legally incapacitated&#xD;
             preventing informed consent from being obtained, or cannot read or comprehend written&#xD;
             material.&#xD;
&#xD;
          -  Active malignancy of any type or history of a malignancy within the last five years&#xD;
             other than basal cell carcinoma.&#xD;
&#xD;
          -  Any active gastrointestinal disease.&#xD;
&#xD;
          -  Use of NSAID within seven days of entering the study (Visit 2).&#xD;
&#xD;
          -  Use of glucosamine sulphate, chondroitin sulphate or any other natural health product&#xD;
             and/or OTC product that claim to be effective for pain and/or OA within 30 days of&#xD;
             entering the study (Visit 2).&#xD;
&#xD;
          -  History of drug abuse or active alcoholism.&#xD;
&#xD;
          -  Any investigational drug within 30 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Beaulieu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Rhymatologie St-Louis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Bessette, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe de recherche en rhumatologie et maladies osseuses</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morin Frédéric, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche Musculo-Squelettique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre Raynauld, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de rhumatologie de Montréal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Rhumatologie de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Rhumatologie St-Louis</name>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Rhumatologie et maladies osseuses</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <name_title>Barry W. Ritz/Vice President for Scientific Affairs</name_title>
    <organization>Atrium Innovations</organization>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Disease of joints</keyword>
  <keyword>Wobenzym® N</keyword>
  <keyword>WOMAC pain score</keyword>
  <keyword>Subject reported pain (VAS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wobenzym</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

